LONDON — The German biotech Tubulis, which is designing a sequence of next-generation chemotherapy remedies, mentioned Wednesday it had raised a $358 million Collection C, a large funding spherical that may assist it push its lead drug candidate into trials in further kinds of most cancers.
Tubulis, primarily based in Munich, is growing a collection of what are generally known as antibody-drug conjugates, medicines which are designed to ship chemo on to tumor websites, unleashing the poisonous remedy on most cancers cells whereas avoiding the whole-body unwanted effects that include conventional chemotherapy.
The corporate’s most superior product, generally known as TUB-040, is being examined in kinds of ovarian and non-small cell lung most cancers. Tubulis mentioned the inflow of cash will permit it to check the molecule in earlier traces of remedy and extra tumor sorts, in addition to increasing work on its complete pipeline.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.